Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Effects of Etifoxine 100 mg and Lorazepam 2 mg on Vigilance and Cognitive Functions in the Elderly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Man or woman aged from 65 to 75 years~* Right-handed subject (Edinburgh Handedness inventory)~* Subject having signed the consent form~* Subject having agreed to be listed on the French National Healthy Volunteers database~* Subject affiliated or beneficiary to French social insurance~Exclusion Criteria:~* Subject presenting a neurological or psychiatric disease notably cognitive, progressing~* Anxious subject (Hamilton score \> 7 and/or Spielberger score \> 51 for a man or \> 61 for a woman)~* Left-handed subject (Edinburgh Handedness inventory)~* Subject presenting a not corrected visual disease or a motor function disease that could interfere with tests realization~* Smoker~* Subject taking one or more psychotropics or apparent products~* Subject having taken, during the previous month, one or more drugs that could interfere with study drugs metabolism~* Subject drinking too much coffee or tea (\> 4 cups per day) or alcohol (\>½ liter of wine or equivalent per day)~* Subject presenting contra-indication to one of the drugs used in the study~* Subject with past history of intolerance to drugs used in the study~* Subject not capable to use the CANTAB cognitive evaluation system~* Subject which may not be able to participate to the whole study~* Subject under tutelage or guardianship~* Subject not able to well-understand French and so to understand cognitive tests~* Subject not capable to swallow capsules~* Subject participating to another study or in exclusion period (3 months after a previous trial).

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- etifoxine (Anxiolytic) (Type: EXPERIMENTAL): etifoxine, 100 mg, a single oral intake
- lorazepam (Type: ACTIVE_COMPARATOR): lorazepam, 2 mg, a single oral intake
- Placebo (Type: PLACEBO_COMPARATOR): 2 capsules of Placebo, a single oral intake

Based on this trial design, predict the completion outcome and termination type (if applicable).